Fluoxetine in the treatment of intention myoclonus.
Some types of intention myoclonus respond to serotonin precursor therapy (e.g., L-5-hydroxytryptophan, L-5HTP). Fluoxetine, a specific serotonin (5HT) uptake blocker, was found to have no antimyoclonic effect when administered by itself to four patients with intention myoclonus. However, in two patients with intention myoclonus responsive to L-5HTP and carbidopa, fluoxetine reduced the required dose of L-5HTP to approximately one-third, with greater antimyoclonic activity, decreased side effects, and reduction in platelet 5HT and plasma 5-hydroxyindoleacetic acid and L-5HTP concentrations. These findings further support the hypothesis that some forms of intention myoclonus are caused by a deficiency of brain 5HT, and suggest that the addition of fluoxetine to L-5HTP and carbidopa may improve antimyoclonic therapy.
D006916:5-Hydroxytryptophan / Q000627:therapeutic use; D000328:Adult; D001792:Blood Platelets / Q000378:metabolism; D002230:Carbidopa / Q000627:therapeutic use; D005260:Female; D005473:Fluoxetine / Q000627:therapeutic use*; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000097:blood; D008297:Male; D008875:Middle Aged; D009207:Myoclonus / Q000188:drug therapy*; D011437:Propylamines / Q000627:therapeutic use*; D012701:Serotonin / Q000097:blood; D013997:Time Factors
D011437:Propylamines; D005473:Fluoxetine; D012701:Serotonin; D006897:Hydroxyindoleacetic Acid; D006916:5-Hydroxytryptophan; D002230:Carbidopa